Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat in JAKi-refractory myelofibrosis (IMbark)
NCT02426086Phase 2Completed
- Sponsor
- Geron Corporation
- Start
- Aug 2015
- Primary completion
- Apr 2018
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 11
01
Overview
A Phase 2 trial of imetelstat in myelofibrosis (MF), sponsored by Geron Corporation. Started Aug 2015; status: completed.
02
Drugs
imetelstat
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02426086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02426086.